KYMRIAH (Novartis Pharmaceuticals Corporation)
Welcome to the PulseAid listing for the KYMRIAH drug offered from Novartis Pharmaceuticals Corporation. This pharmaceutical is classified as a CELLULAR THERAPY. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same CELLULAR THERAPY drug type category.
| LABELER NAME / MANUFACTURER: | Novartis Pharmaceuticals Corporation |
| NON-PROPRIETARY NAME: | tisagenlecleucel |
| SUBSTANCE NAME: | TISAGENLECLEUCEL |
| TYPE: | CELLULAR THERAPY |
| PHARMA CLASS: | |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION, SUSPENSION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2017-08-30 |
| END MARKETING DATE: | 0000-00-00 |
KYMRIAH CELLULAR THERAPY Details:
| Item Description | KYMRIAH from Novartis Pharmaceuticals Corporation |
| LABELER NAME: | Novartis Pharmaceuticals Corporation |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 2000000(1-Jan) |
| START MARKETING DATE: | 2017-08-30 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0078-0846_22dc1c28-0cf5-4290-b499-eb5391a232c2 |
| PRODUCT NDC: | 0078-0846 |
| APPLICATION NUMBER: | BLA125646 |
Other TISAGENLECLEUCEL Pharmaceutical Manufacturers / Labelers:
